The Transverse Myelitis Association (TMA) is a not-for-profit international foundation dedicated to the support of children, adolescents, and adults with a spectrum of rare neuro-immunologic disorders including: Acute Disseminated Encephalomyelitis (ADEM), Acute Flaccid Myelitis (AFM), Neuromyelitis Optica (NMO), Optic Neuritis (ON) and Transverse Myelitis (TM).
Founded in 1994 by family members and persons with these diagnoses, the TMA was incorporated on November 25, 1996 in the state of Washington and we became a 501(c)(3) organization on December 9, 1996.
Membership of the TMA includes individuals with these rare disorders, their family members and caregivers, and the medical professionals who treat individuals with these disorders. The TMA currently has approximately 10,000 members from more than 80 different countries and has a large number of support groups across the United States and around the world. There are no membership fees.
Our goal is to advance a comprehensive network dedicated to the care of our members through the development of professionals specializing in these rare disorders, centers of excellence focused on these disorders around the world, and our international community support system. Additionally, we are focused on strategic research priorities with our Board of Directors and Scientific Council to further the understanding of the causes of AFM, TM, ADEM, ON and NMO, and to develop new acute and regenerative therapies.
We provide numerous services for our members. We offer a support network between persons with these disorders through local support groups located throughout the world. To attract new clinicians and researchers into the rare neuro-immunologic disorder discipline, we have established the James T. Lubin Fellowship. We publish newsletters to update the community on current research and various community outreach events and opportunities. We support and conduct various educational events through symposia and workshops involving clinicians, scientists, and individuals affected by these disorders for the exchange of information regarding research and treatment strategies, including annual family camps for children with these disorders and their family members.